Medacta reported 1H22 orthopedic sales of $215.5 million, +19% compared to the first half of 2021.
Continued salesforce expansion, new customer acquisition and new product introductions drove Medacta’s growth. COVID restrictions and hospital staffing shortages in the U.S. and Australia offset some of the company’s gains, however.
Medacta’s NextAR system reached 1,000 surgeries during its limited release. The hardware requires a limited capital investment and features low-cost single-use instruments, making it ideal for the ASC market in the U.S.
During the first half, the company achieved the milestone of 100 NextAR systems in the market. The May full market release of the shoulder application helped drive adoption. The system expanded its international reach in late June with regulatory approval in Japan.
Given its first-half performance, Medacta expects to achieve the upper end of its $408 million to $422 million guidance range.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
1H22
1H21
$ Chg
% Chg
Joint Replacement
$194.7
$163.8
$30.9
18.9%
Knees
$78.8
$64.7
$14.1
21.8%
Hips
$103.4
$90.1
$13.3
14.7%
Extremities
$12.5
$9.0
$3.5
39.3%
Spine
$20.2
$16.9
$3.3
19.4%
Sports Medicine
$0.6
$0.3
$0.3
85%
Total
$215.5
$181.0
$34.4
19%
Orthopedic Sales by Geography
1H22
1H21
$ Chg
% Chg
US
$65.5
$53.6
$11.9
22.2%
OUS
$150.0
$127.4
$22.5
17.7%
EMEA
$96.2
$77.7
$18.5
23.8%
APAC
$45.7
$43.9
$1.8
4.1%
ROW
$8.1
$5.8
$2.2
38.5%
Total
$215.5
$181.0
$34.4
19%
Medacta reported 1H22 orthopedic sales of $215.5 million, +19% compared to the first half of 2021.
Continued salesforce expansion, new customer acquisition and new product introductions drove Medacta's growth. COVID restrictions and hospital staffing shortages in the U.S. and Australia offset some of the company's gains, however. ...
Medacta reported 1H22 orthopedic sales of $215.5 million, +19% compared to the first half of 2021.
Continued salesforce expansion, new customer acquisition and new product introductions drove Medacta’s growth. COVID restrictions and hospital staffing shortages in the U.S. and Australia offset some of the company’s gains, however.
Medacta’s NextAR system reached 1,000 surgeries during its limited release. The hardware requires a limited capital investment and features low-cost single-use instruments, making it ideal for the ASC market in the U.S.
During the first half, the company achieved the milestone of 100 NextAR systems in the market. The May full market release of the shoulder application helped drive adoption. The system expanded its international reach in late June with regulatory approval in Japan.
Given its first-half performance, Medacta expects to achieve the upper end of its $408 million to $422 million guidance range.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
1H22
1H21
$ Chg
% Chg
Joint Replacement
$194.7
$163.8
$30.9
18.9%
Knees
$78.8
$64.7
$14.1
21.8%
Hips
$103.4
$90.1
$13.3
14.7%
Extremities
$12.5
$9.0
$3.5
39.3%
Spine
$20.2
$16.9
$3.3
19.4%
Sports Medicine
$0.6
$0.3
$0.3
85%
Total
$215.5
$181.0
$34.4
19%
Orthopedic Sales by Geography
1H22
1H21
$ Chg
% Chg
US
$65.5
$53.6
$11.9
22.2%
OUS
$150.0
$127.4
$22.5
17.7%
EMEA
$96.2
$77.7
$18.5
23.8%
APAC
$45.7
$43.9
$1.8
4.1%
ROW
$8.1
$5.8
$2.2
38.5%
Total
$215.5
$181.0
$34.4
19%
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
